There are approved second (treating NSCLC harbouring activating EGFR mutations) and third (i.e., osimertinib, targeting NSCLC carrying EGFR-TKI–sensitising and EGFR p.Thr790Met (T790M) resistance mutations) (10) generation EGFT-TKIs in China. Here, EGFR is linked to non-small cell lung carcinoma.